{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:32:38Z","timestamp":1777987958634,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Monkeypox (mpox), a zoonotic viral infection, poses a global threat that is being acknowledged at the national and international levels. This systematic review aims to identify and characterize interventional clinical trials for mpox.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      All interventional clinical trials registered at\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      for mpox were searched up to January 6, 2023. We described the characteristics of interventional clinical trials, and drug interventions (including drugs and vaccines).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of January 6, 2023, there were 10 clinical trials in the\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      registry that met our criteria. Most of the interventional clinical trials were focused on the treatment (\n                      <jats:italic>N<\/jats:italic>\n                      = 4, 40%) and prevention (\n                      <jats:italic>N<\/jats:italic>\n                      = 4, 40%) of mpox. From the 10 trials, 50% used random treatment allocation, and six (60%) chose the parallel assignment intervention model. All 10 studies were blinded, and six were open-label blinded. The largest proportion of the clinical trials (\n                      <jats:italic>N<\/jats:italic>\n                      = 4, 40%) were registered in Europe, followed by America (\n                      <jats:italic>N<\/jats:italic>\n                      = 3, 30%) and Africa and others (\n                      <jats:italic>N<\/jats:italic>\n                      = 3, 30%). The JYNNEOS vaccine (40%), followed by Tecovirimat (30%) were the most frequently studied drugs used against mpox.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      A limited number of clinical trials have been registered on\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      since the first case of mpox was reported. Therefore, there is an urgent need to conduct large-scale randomized clinical trials to assess the safety and efficacy of the drugs and vaccines being used against the mpox virus.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2023.1144325","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T02:14:28Z","timestamp":1678328068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Characterization of interventional clinical trials for monkeypox; systematic review of ClinicalTrials.gov database"],"prefix":"10.3389","volume":"11","author":[{"given":"Nasser M.","family":"Alorfi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad S.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e03066","DOI":"10.7189\/jogh.12.03066","article-title":"Unprecedented rise of monkeypox in Europe and America: Are Asian countries ready for a new outbreak during the ongoing COVID-19 pandemic?","volume":"12","author":"Khan","year":"2022","journal-title":"J Glob Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00415-022-11339-w","article-title":"Monkeypox virus from neurological complications to neuroinvasive properties: Current status and future perspectives","volume":"270","author":"Sepehrinezhad","year":"2023","journal-title":"J Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104069","DOI":"10.1016\/j.amsu.2022.104069","article-title":"The outbreak of monkeypox 2022: An overview","volume":"79","author":"Hraib","year":"2022","journal-title":"Ann Med Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.3390\/ijms23147866","article-title":"Monkeypox: A new threat?","volume":"23","author":"Kmiec","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"112496","DOI":"10.3390\/v14112496","article-title":"Prevention and treatment of monkeypox: A systematic review of preclinical studies","volume":"14","author":"Sudarmaji","year":"2022","journal-title":"Viruses"},{"key":"B6","volume-title":"2022 Mpox (Monkeypox) Outbreak: Global Trends","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","first-page":"bmj.o1489","DOI":"10.1136\/bmj.o1489","article-title":"Monkeypox: WHO to rename disease to prevent stigma","volume":"2022","author":"Taylor","year":"2022","journal-title":"Br Med J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101078","DOI":"10.1016\/j.nmni.2022.101078","article-title":"Factors associated with geographic variations in the 2022 monkeypox outbreak; A systematic review","volume":"51","author":"Abu-Hammad","year":"2023","journal-title":"New Microbes New Infect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104051","DOI":"10.1016\/j.amsu.2022.104051","article-title":"Monkeypox has devastated the world; should we prepare for the outbreak of a new pandemic?","volume":"79","author":"Awan","year":"2022","journal-title":"Ann Med Surg."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106745","DOI":"10.1016\/j.ijsu.2022.106745","article-title":"Monkeypox: An extra burden on global health","volume":"104","author":"Saied","year":"2022","journal-title":"Int J Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ijid.2022.06.047","article-title":"Vaccination for monkeypox prevention in persons with high-risk sexual behaviours to control on-going outbreak of monkeypox virus clade 3","volume":"122","author":"Petersen","year":"2022","journal-title":"Int J Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12519-022-00624-3","article-title":"Diagnosis, treatment, and prevention of monkeypox in children: An experts' consensus statement","volume":"2022","author":"Jiang","year":"2022","journal-title":"World J Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104657","DOI":"10.1016\/j.amsu.2022.104657","article-title":"Monkeypox outbreak amidst COVID-19 reemergence in the European Region: Challenges, efforts, and recommendations","volume":"82","author":"Zaheer","year":"2022","journal-title":"Ann Med Surg."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21203\/rs.3.rs-1164646\/v1","article-title":"Update on the clinical trial landscape: analysis of ClinicalTrials. gov registration data, 2000\u20132020","volume":"23","author":"Gresham","year":"2022","journal-title":"Trials"},{"key":"B15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/0972-6748.62274","article-title":"Hypothesis testing, type I and type II errors","volume":"18","author":"Banerjee","year":"2009","journal-title":"Ind Psychiatry J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.22207\/JPAM.16.SPL1.21","article-title":"An overview on monkeypox, current paradigms and advances in its vaccination, treatment and clinical management: Trends, scope, promise and challenges","volume":"16","author":"Sharma","year":"","journal-title":"J Pure Appl Microbiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e009838","DOI":"10.1136\/bmjgh-2022-009838","article-title":"Availability, scope and quality of monkeypox clinical management guidelines globally: A systematic review","volume":"7","author":"Webb","year":"2022","journal-title":"Br Med J Glob Health."},{"key":"B18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2210125","article-title":"Tecovirimat and the treatment of monkeypox\u2014past, present, and future considerations","volume":"387","author":"Sherwat","year":"2022","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jama.2022.15336","article-title":"Compassionate use of tecovirimat for the treatment of monkeypox infection","volume":"328","author":"Desai","year":"2022","journal-title":"J Am Med Assoc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"888079","DOI":"10.3389\/fphar.2022.888079","article-title":"The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review","volume":"13","author":"Palmer","year":"2022","journal-title":"Front Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109346","DOI":"10.1016\/j.intimp.2022.109346","article-title":"Monkeypox virus vaccine evolution and global preparedness for vaccination","volume":"113","author":"Chakraborty","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"102441","DOI":"10.1016\/j.tmaid.2022.102441","article-title":"A review on insights and lessons from COVID-19 to the prevent of monkeypox pandemic","volume":"50","author":"Hemati","year":"2022","journal-title":"Travel Med Infect Dis."},{"key":"B23","unstructured":"Vaccines.232022"},{"key":"B24","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40265-022-01742-y","article-title":"Prevention and treatment of monkeypox","volume":"82","author":"Rizk","year":"2022","journal-title":"Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2022.2113058","article-title":"Prevention and treatment of monkeypox","volume":"2022","author":"Rizk","year":"2022","journal-title":"Drugs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1080\/14787210.2022.2113058","article-title":"Therapeutic strategies to address monkeypox","volume":"20","author":"McCarthy","year":"2022","journal-title":"Expert Rev Anti Infect Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s11357-022-00611-6","article-title":"Monkeypox: Considerations for the understanding and containment of the current outbreak in non-endemic countries","volume":"44","author":"Quarleri","year":"2022","journal-title":"Geroscience."},{"key":"B28","doi-asserted-by":"publisher","first-page":"o1379","DOI":"10.1136\/bmj.o1379","article-title":"Monkeypox: Healthcare workers will be offered smallpox vaccine as UK buys 20 000 doses","volume":"377","author":"Mahase","year":"2022","journal-title":"Br Med J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/v9100283","article-title":"Assessing monkeypox virus prevalence in small mammals at the human\u2013animal interface in the Democratic Republic of the Congo","volume":"9","author":"Doty","year":"2017","journal-title":"Viruses."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3a4","DOI":"10.15585\/mmwr.mm7203a4","article-title":"Epidemiology of human Mpox\u2014Worldwide, 2018\u20132021","volume":"72","author":"McCollum","year":"2023","journal-title":"Morbid Mortal Weekly Rep"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1144325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T02:14:33Z","timestamp":1678328073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1144325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2023.1144325"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1144325","relation":{"is-referenced-by":[{"id-type":"doi","id":"10.1007\/s00203-025-04695-4","asserted-by":"object"}]},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"article-number":"1144325"}}